For Patients

For Patients

For patients with recurrent/refractory cancers who have exhausted current standards of care, First Ascent offers a breakthrough option to define new treatment approaches. 

For patients with recurrent/refractory cancers who have exhausted current standards of care, First Ascent offers a breakthrough option to define new treatment approaches.

First Ascent’s first-in-kind solutions focus on you — your cancer, your tumor, your biology — in a highly individualized way — vs. the historical perspective of traditional standards of care limited to historical analysis.

We are currently involved in two clinical studies NTC05857969 & NCT06024603. Our mission is to make this platform accessible outside of a clinical trial by Q3 2024. Giving those with the rarest cancers a fighting chance. A treatment plan for every type of cancer including all solid and all liquid tumors.

First Ascent’s first-in-kind solutions focus on you — your cancer, your tumor, your biology — in a highly individualized way — vs. the historical perspective of traditional standards of care limited to historical analysis.

Our Drug Prediction Platform, originally created to give those with the rarest cancers a fighting chance, now can develop treatment plans for every type of cancer including all solid and all liquid tumors.

First Ascent’s first-in-kind solutions focus on you — your cancer, your tumor, your biology — in a highly individualized way — vs. the historical perspective of traditional standards of care limited to historical analysis.

Our Drug Prediction Platform, originally created to give those with the rarest cancers a fighting chance, now can develop treatment plans for every type of cancer including all solid and all liquid tumors.

Helping Patients

The First Ascent Biomedical Ex Vivo Drug Response Identification & Validation Engine – xDRIVE

First Ascent Biopsy Image

1. Biopsy

Biopsy received from patient within 24 hours.

First Ascent Bio Cell Enrichment

2. Cell Enrichment

Rapidly grow therapy resistant cells and tumor bulk.

First Ascent Bio Drug Screening

3. Drug Screening

Test 100s of FDA approved drugs.

First Ascent Biomedical AI/ML Analysis

4. AI/ML Analysis

AI/ML examines every weakness.

5. Custom Treatment Recommendation Report

Because each person is unique at the DNA level and so is their cancer, First Ascent develops fully personalized, data-driven drug treatment plans.
Our Drug Prediction Platform uses the patient’s genetic data, identifies weaknesses in their tumor, tests these against 100s of existing drugs on the patient’s own cells, & designs a treatment plan, complete with rationale, for patients & their physicians, with a median time of 10 days.
Our published validation studies with major cancer centers indicate a 13.5-fold median improvement in progression-free survival for refractory and recurrent cancers
Full Customer Service – We keep you at the center of your cancer treatment. Our results are delivered to your oncologist and to you. We will keep you informed of timing and delivery. Once your report is delivered, we’re here to help answer any questions.

Coming Soon Get Started with Us in Four Simple Steps!

1. Start

Start the conversation with your provider about alternate treatment options through First Ascent Biomedical.

2. Ship

We work with your doctor to ship a live tumor tissue sample overnight to First Ascent’s cutting-edge CLIA certified laboratories.

3. Test

We test drugs on your cancer cells to identify your cancer’s unique vulnerabilities, supported by DNA and RNA analysis.

4. Deliver

Your top treatment options with the underlying data and evidence are delivered to your physician as a concise and actionable report, complete with rationale, on average in 10 days.

For more detail see our Frequently Asked Questions.

Publication and Pharma Partners